News
CMXHF
128.50
NaN%
--
CSL (CMXHF) Gets a Hold from Macquarie
TipRanks · 4d ago
CSL Seqirus expands U.S. availability of influenza vaccine
TipRanks · 4d ago
Citi Sticks to Its Hold Rating for CSL (CMXHF)
TipRanks · 09/23 23:35
CSL Continues Active On-Market Share Buy-Back Program
TipRanks · 09/17 22:48
Haemonetics upgraded to Buy at BofA on supply deal with CSL
Seeking Alpha · 09/17 14:16
CSL Sets Date and Details for 2026 Annual General Meeting in Melbourne
TipRanks · 09/16 22:42
Positive Report for CSL (CMXHF) from Ord Minnett
TipRanks · 09/16 01:05
CSL Updates Market on Progress of Ongoing Share Buy‑Back
TipRanks · 09/15 22:55
CSL upgraded to Outperform from Sector Perform at RBC Capital
TipRanks · 09/15 20:00
CSL Reports Ongoing Daily On-Market Share Buy-Back Activity
TipRanks · 09/14 23:15
CSL Updates Dividend Notice With New Currency Conversion Details
TipRanks · 09/13 22:56
BioCryst Pharmaceuticals: Why The Selloff Could Be An Opportunity
Seeking Alpha · 09/11 14:16
Citi Sticks to Their Hold Rating for CSL (CMXHF)
TipRanks · 09/10 00:06
CSL Appoints J.P. Morgan as Broker for On‑Market Share Buy‑Back
TipRanks · 09/08 06:53
CSL Seeks ASX Quotation for New Shares from Employee Incentive Plan
TipRanks · 09/08 06:53
CSL Issues 1.9 Million Unquoted Rights Under Employee Incentive Scheme
TipRanks · 09/08 06:33
CSL Adjusts Capital Structure as 275,104 Conditional Rights Lapse
TipRanks · 09/07 07:06
CSL Notifies Cessation of CSLAL Rights Securities on ASX
TipRanks · 09/03 23:00
CSL Director Alison Watkins Increases Indirect Equity Exposure via Rights Plan
TipRanks · 09/03 07:23
CSL Director Cameron Price Increases Equity Exposure via Rights Plan
TipRanks · 09/03 07:01
More
Webull provides a variety of real-time CMXHF stock news. You can receive the latest news about CSL through multiple platforms. This information may help you make smarter investment decisions.
About CMXHF
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.